{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:20Z","timestamp":1740107720734,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05898-y","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T06:16:51Z","timestamp":1630304211000},"page":"4367-4368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term glucocorticoid treatment in patients with polymyalgia rheumatica: can we just move a step forward? Comments on \u201cLong-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis\u201d"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-3814","authenticated-orcid":false,"given":"Ciro","family":"Manzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"5898_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05819-z","author":"A Floris","year":"2021","unstructured":"Floris A, Piga M, Chessa E et al (2021) Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05819-z","journal-title":"Clin Rheumatol"},{"key":"5898_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/rheumatology\/key431","volume":"58","author":"C Manzo","year":"2019","unstructured":"Manzo C, Milchert M, Natale M, Brzosko M (2019) Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis. Rheumatology (Oxford) 58:921\u2013923. https:\/\/doi.org\/10.1093\/rheumatology\/key431","journal-title":"Rheumatology (Oxford)"},{"key":"5898_CR3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.55563\/clinexprheumatol\/gdps1r","volume":"39","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, Den Broeder N, Boers N et al (2021) Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica? Clin Exp Rheumatol 39:32\u201337","journal-title":"Clin Exp Rheumatol"},{"key":"5898_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/1756-185X.14054","volume":"24","author":"C Manzo","year":"2021","unstructured":"Manzo C (2021) C-reactive protein concentrations as predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica. Int J Rheum Dis 24:284\u2013285. https:\/\/doi.org\/10.1111\/1756-185X.14054","journal-title":"Int J Rheum Dis"},{"key":"5898_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2474-12-94","volume":"12","author":"MA Cimmino","year":"2011","unstructured":"Cimmino MA, Parodi M, Montecucco C, Caporali R (2011) The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 12:94. https:\/\/doi.org\/10.1186\/1471-2474-12-94","journal-title":"BMC Musculoskelet Disord"},{"key":"5898_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/030097401753180327","volume":"30","author":"G Myklebust","year":"2001","unstructured":"Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 30:260\u20137. https:\/\/doi.org\/10.1080\/030097401753180327","journal-title":"Scand J Rheumatol"},{"key":"5898_CR7","first-page":"655","volume":"18","author":"M Cutolo","year":"2000","unstructured":"Cutolo M, Straub RH (2000) Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease. Clin Exp Rheumatol 18:655\u2013658","journal-title":"Clin Exp Rheumatol"},{"key":"5898_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/rheumatology\/39.6.624","volume":"39","author":"RH Straub","year":"2000","unstructured":"Straub RH, Gluck T, Cutolo M et al (2000) The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumor necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 39:624\u2013631. https:\/\/doi.org\/10.1093\/rheumatology\/39.6.624","journal-title":"Rheumatology (Oxford)"},{"key":"5898_CR9","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1093\/rheumatology\/keaa011","volume":"59","author":"SW Borresen","year":"2020","unstructured":"Borresen SW, Thorgrimsen TB, Jensen B et al (2020) Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach. Rheumatology (Oxford) 59:2764\u20132773. https:\/\/doi.org\/10.1093\/rheumatology\/keaa011","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T07:52:44Z","timestamp":1673164364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5898"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05898-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}